# Veracyte, Inc.: financial statements, quarterly

VCYT · Nasdaq · CIK 1384101 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vcyt.md) · [Financials](/companies/vcyt/financials.md) · [Filings](/companies/vcyt/filings.md) · [Insiders](/companies/vcyt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vcyt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [90.1](/filings/0001384101-24-000162.md) | [98.2 d](/filings/0001384101-26-000010.md) | [96.8](/filings/0001384101-25-000060.md) | [114](/filings/0001384101-25-000110.md) | [116](/filings/0001384101-25-000130.md) | [119 d](/filings/0001384101-26-000010.md) | [114](/filings/0001384101-26-000031.md) | [130](/filings/0001384101-26-000044.md) | [132](/filings/0001384101-25-000130.md) | [141 d](/filings/0001384101-26-000010.md) | [139](/filings/0001384101-26-000031.md) | [150](/filings/0001384101-26-000044.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | [57.7](/filings/0001384101-24-000162.md) | [64.8 d](/filings/0001384101-26-000010.md) | [62.5](/filings/0001384101-25-000060.md) | [77.9](/filings/0001384101-25-000110.md) | [79.0](/filings/0001384101-25-000130.md) | [78.8 d](/filings/0001384101-26-000010.md) | [79.5](/filings/0001384101-26-000031.md) | [89.8](/filings/0001384101-26-000044.md) | [91.3](/filings/0001384101-25-000130.md) | [102 d](/filings/0001384101-26-000010.md) | [101](/filings/0001384101-26-000031.md) | [109](/filings/0001384101-26-000044.md) |
| Research and development | $m | [13.3](/filings/0001384101-24-000162.md) | [18.7 d](/filings/0001384101-26-000010.md) | [16.0](/filings/0001384101-25-000060.md) | [16.5](/filings/0001384101-25-000110.md) | [17.6](/filings/0001384101-25-000130.md) | [19.3 d](/filings/0001384101-26-000010.md) | [17.7](/filings/0001384101-26-000031.md) | [16.3](/filings/0001384101-26-000044.md) | [16.0](/filings/0001384101-25-000130.md) | [20.8 d](/filings/0001384101-26-000010.md) | [27.1](/filings/0001384101-26-000031.md) | [29.4](/filings/0001384101-26-000044.md) |
| Operating income | $m | [(31.7)](/filings/0001384101-24-000162.md) | [(35.5) d](/filings/0001384101-26-000010.md) | [(4.7)](/filings/0001384101-25-000060.md) | [4.6](/filings/0001384101-25-000110.md) | [12.0](/filings/0001384101-25-000130.md) | [4.2 d](/filings/0001384101-26-000010.md) | [2.9](/filings/0001384101-26-000031.md) | [(5.3)](/filings/0001384101-26-000044.md) | [22.9](/filings/0001384101-25-000130.md) | [37.2 d](/filings/0001384101-26-000010.md) | [22.6](/filings/0001384101-26-000031.md) | [23.0](/filings/0001384101-26-000044.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(0.2)](/filings/0001384101-24-000162.md) | [(2.2) d](/filings/0001384101-26-000010.md) | [(0.0)](/filings/0001384101-25-000060.md) | [1.6](/filings/0001384101-25-000110.md) | [1.7](/filings/0001384101-25-000130.md) | [(1.7) d](/filings/0001384101-26-000010.md) | [0.4](/filings/0001384101-26-000031.md) | [2.2](/filings/0001384101-26-000044.md) | [(0.2)](/filings/0001384101-25-000130.md) | [(0.5) d](/filings/0001384101-26-000010.md) | [1.3](/filings/0001384101-26-000031.md) | [1.0](/filings/0001384101-26-000044.md) |
| Net income | $m | [(29.6)](/filings/0001384101-24-000162.md) | [(28.3) d](/filings/0001384101-26-000010.md) | [(1.9)](/filings/0001384101-25-000060.md) | [5.7](/filings/0001384101-25-000110.md) | [15.2](/filings/0001384101-25-000130.md) | [5.1 d](/filings/0001384101-26-000010.md) | [7.0](/filings/0001384101-26-000031.md) | [(1.0)](/filings/0001384101-26-000044.md) | [19.1](/filings/0001384101-25-000130.md) | [41.1 d](/filings/0001384101-26-000010.md) | [28.7](/filings/0001384101-26-000031.md) | [25.5](/filings/0001384101-26-000044.md) |
| Diluted EPS | $ per share | [(0.41)](/filings/0001384101-24-000162.md) | not reported | [(0.02)](/filings/0001384101-25-000060.md) | [0.07](/filings/0001384101-25-000110.md) | [0.19](/filings/0001384101-25-000130.md) | not reported | [0.09](/filings/0001384101-26-000031.md) | [(0.01)](/filings/0001384101-26-000044.md) | [0.24](/filings/0001384101-25-000130.md) | not reported | [0.35](/filings/0001384101-26-000031.md) | [0.31](/filings/0001384101-26-000044.md) |
| Basic EPS | $ per share | [(0.41)](/filings/0001384101-24-000162.md) | not reported | [(0.02)](/filings/0001384101-25-000060.md) | [0.07](/filings/0001384101-25-000110.md) | [0.20](/filings/0001384101-25-000130.md) | not reported | [0.09](/filings/0001384101-26-000031.md) | [(0.01)](/filings/0001384101-26-000044.md) | [0.24](/filings/0001384101-25-000130.md) | not reported | [0.36](/filings/0001384101-26-000031.md) | [0.32](/filings/0001384101-26-000044.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [202](/filings/0001384101-23-000163.md) | [216](/filings/0001384101-26-000010.md) | [209](/filings/0001384101-24-000067.md) | [236](/filings/0001384101-24-000118.md) | [274](/filings/0001384101-24-000162.md) | [239](/filings/0001384101-26-000010.md) | [186](/filings/0001384101-25-000060.md) | [219](/filings/0001384101-25-000110.md) | [316](/filings/0001384101-25-000130.md) | [363](/filings/0001384101-26-000044.md) | [263](/filings/0001384101-26-000031.md) | [300](/filings/0001384101-26-000044.md) |
| Current assets | $m | [271](/filings/0001384101-23-000163.md) | [286](/filings/0001384101-25-000014.md) | [290](/filings/0001384101-24-000067.md) | [321](/filings/0001384101-24-000118.md) | [357](/filings/0001384101-24-000162.md) | [372](/filings/0001384101-26-000010.md) | [383](/filings/0001384101-25-000060.md) | [415](/filings/0001384101-25-000110.md) | [449](/filings/0001384101-25-000130.md) | [488](/filings/0001384101-26-000044.md) | [522](/filings/0001384101-26-000031.md) | [575](/filings/0001384101-26-000044.md) |
| Total assets | $m | [1,125](/filings/0001384101-23-000163.md) | [1,115](/filings/0001384101-25-000014.md) | [1,200](/filings/0001384101-24-000067.md) | [1,234](/filings/0001384101-24-000118.md) | [1,275](/filings/0001384101-24-000162.md) | [1,300](/filings/0001384101-26-000010.md) | [1,315](/filings/0001384101-25-000060.md) | [1,344](/filings/0001384101-25-000110.md) | [1,368](/filings/0001384101-25-000130.md) | [1,406](/filings/0001384101-26-000044.md) | [1,436](/filings/0001384101-26-000031.md) | [1,486](/filings/0001384101-26-000044.md) |
| Current liabilities | $m | [57.3](/filings/0001384101-23-000163.md) | [61.2](/filings/0001384101-25-000014.md) | [58.1](/filings/0001384101-24-000067.md) | [72.3](/filings/0001384101-24-000118.md) | [70.3](/filings/0001384101-24-000162.md) | [78.6](/filings/0001384101-26-000010.md) | [75.1](/filings/0001384101-25-000060.md) | [76.4](/filings/0001384101-25-000110.md) | [72.2](/filings/0001384101-25-000130.md) | [59.9](/filings/0001384101-26-000044.md) | [56.1](/filings/0001384101-26-000031.md) | [62.7](/filings/0001384101-26-000044.md) |
| Total liabilities | $m | [70.9](/filings/0001384101-23-000163.md) | [70.8](/filings/0001384101-25-000014.md) | [81.4](/filings/0001384101-24-000067.md) | [102](/filings/0001384101-24-000118.md) | [99.0](/filings/0001384101-24-000162.md) | [124](/filings/0001384101-26-000010.md) | [120](/filings/0001384101-25-000060.md) | [123](/filings/0001384101-25-000110.md) | [110](/filings/0001384101-25-000130.md) | [96.4](/filings/0001384101-26-000044.md) | [92.0](/filings/0001384101-26-000031.md) | [98.0](/filings/0001384101-26-000044.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [1,054](/filings/0001384101-24-000162.md) | [1,044](/filings/0001384101-26-000010.md) | [1,119](/filings/0001384101-25-000110.md) | [1,133](/filings/0001384101-25-000130.md) | [1,176](/filings/0001384101-25-000130.md) | [1,176](/filings/0001384101-26-000044.md) | [1,195](/filings/0001384101-26-000044.md) | [1,221](/filings/0001384101-26-000044.md) | [1,258](/filings/0001384101-25-000130.md) | [1,310](/filings/0001384101-26-000044.md) | [1,344](/filings/0001384101-26-000044.md) | [1,388](/filings/0001384101-26-000044.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [14.2 d](/filings/0001384101-24-000162.md) | [15.6 d](/filings/0001384101-26-000010.md) | [(9.0)](/filings/0001384101-25-000060.md) | [29.6 d](/filings/0001384101-25-000110.md) | [30.0 d](/filings/0001384101-25-000130.md) | [24.5 d](/filings/0001384101-26-000010.md) | [5.4](/filings/0001384101-26-000031.md) | [33.6 d](/filings/0001384101-26-000044.md) | [44.8 d](/filings/0001384101-25-000130.md) | [52.6 d](/filings/0001384101-26-000010.md) | [35.2](/filings/0001384101-26-000031.md) | [45.8 d](/filings/0001384101-26-000044.md) |
| Capital expenditure | $m | [2.8 d](/filings/0001384101-24-000162.md) | [2.5 d](/filings/0001384101-26-000010.md) | [2.1](/filings/0001384101-25-000060.md) | [2.8 d](/filings/0001384101-25-000110.md) | [2.2 d](/filings/0001384101-25-000130.md) | [4.1 d](/filings/0001384101-26-000010.md) | [1.8](/filings/0001384101-26-000031.md) | [1.3 d](/filings/0001384101-26-000044.md) | [2.8 d](/filings/0001384101-25-000130.md) | [3.8 d](/filings/0001384101-26-000010.md) | [3.0](/filings/0001384101-26-000031.md) | [2.9 d](/filings/0001384101-26-000044.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q1 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [71.7](/filings/0001384101-23-000163.md) | [72.2](/filings/0001384101-24-000067.md) | [72.5](/filings/0001384101-24-000118.md) | [72.8](/filings/0001384101-24-000162.md) | [74.8](/filings/0001384101-25-000060.md) | [77.2](/filings/0001384101-25-000110.md) | [78.5](/filings/0001384101-25-000130.md) | [80.1](/filings/0001384101-26-000031.md) | [78.4](/filings/0001384101-26-000044.md) | [79.7](/filings/0001384101-25-000130.md) | [81.3](/filings/0001384101-26-000031.md) | [82.1](/filings/0001384101-26-000044.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 80,390,731 at 2026-07-27, from the cover of the [10-Q filed 2026-07-31](/filings/0001384101-26-000044.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.